Clinicopathologic features of TP53-mutated myeloid disease with less than 10% blasts
| Characteristic . | MDS-TP53 by ICC and WHO (n = 35) . | MDS-TP53 by ICC only (n = 10) . | P value . |
|---|---|---|---|
| Age at dx (y), median (range) | 68.5 (36-83.2) | 70.2 (60.6-84) | NS |
| Sex, male, n (%) | 14 (40) | 5 (50) | NS |
| CBC at dx, median (range) | |||
| ANC, ×103/μL | 1.4 (0.2-11.5) | 0.48 (0.4-2.0) | NS |
| Hb, g/dL | 8.5 (7-12.4) | 8.8 (5.6-13.8) | NS |
| Plt, ×103/μL | 54 (9-347) | 75 (7-226) | NS |
| BM blast %, median (range) | 3.0 (0-9.5) | 5.5 (0.5-9.0) | NS |
| CK, n (%) | 32 (94) | 10 (100) | NS |
| MK, n (%) | 30 (88) | 9 (90) | NS |
| TP53 VAF, median (range) | 45.7 (14.4-97) | 30 (11.8-45) | .02 |
| 0 additional mutations, n (%) | 24 (69) | 7 (70) | NS |
| HMA therapy, n (%) | 23 (66) | 7 (70) | NS |
| Stem cell transplant, n (%) | 6 (17) | 3 (30) | NS |
| Characteristic . | MDS-TP53 by ICC and WHO (n = 35) . | MDS-TP53 by ICC only (n = 10) . | P value . |
|---|---|---|---|
| Age at dx (y), median (range) | 68.5 (36-83.2) | 70.2 (60.6-84) | NS |
| Sex, male, n (%) | 14 (40) | 5 (50) | NS |
| CBC at dx, median (range) | |||
| ANC, ×103/μL | 1.4 (0.2-11.5) | 0.48 (0.4-2.0) | NS |
| Hb, g/dL | 8.5 (7-12.4) | 8.8 (5.6-13.8) | NS |
| Plt, ×103/μL | 54 (9-347) | 75 (7-226) | NS |
| BM blast %, median (range) | 3.0 (0-9.5) | 5.5 (0.5-9.0) | NS |
| CK, n (%) | 32 (94) | 10 (100) | NS |
| MK, n (%) | 30 (88) | 9 (90) | NS |
| TP53 VAF, median (range) | 45.7 (14.4-97) | 30 (11.8-45) | .02 |
| 0 additional mutations, n (%) | 24 (69) | 7 (70) | NS |
| HMA therapy, n (%) | 23 (66) | 7 (70) | NS |
| Stem cell transplant, n (%) | 6 (17) | 3 (30) | NS |
Abbreviations are explained in Tables 1 and 2.